CHU Helora

The CHU Helora team is investigating conditions that affect the heart and blood vessels, aiming to improve long‑term outcomes and reduce serious events such as heart attacks and strokes.

• Acute Coronary Syndrome and secondary prevention strategies
• Evaluation of milvexian to lower major adverse cardiovascular events
• Impact of evolocumab on coronary heart disease mortality and myocardial infarction
• Management of resistant hypertension with novel agents

These studies reflect CHU Helora’s commitment to advancing cardiovascular care for patients across Belgium.

Research at the site focuses on inflammatory bowel disorders and gastrointestinal cancers, seeking better therapies and surgical approaches.

• Clinical assessment of filgotinib in ulcerative colitis
• Trials of ABX464 for moderate to severe Crohn's disease
• Neoadjuvant strategies for locally advanced rectal cancer, including short‑course radiotherapy
• Evaluation of chemotherapy plus stereotactic body radiation for borderline resectable pancreatic adenocarcinoma

The department aims to enhance disease control and quality of life for patients with digestive system conditions.

The immunology program explores autoimmune and inflammatory disorders, testing biologic and small‑molecule agents to achieve durable remission.

• Long‑term safety of bimekizumab in psoriatic arthritis
• Comparison of upadacitinib with placebo and adalimumab in rheumatoid arthritis
• Secukinumab maintenance versus withdrawal in non‑radiographic axial spondyloarthritis
• Assessment of tirgulixostat for gout with hyperuricemia

CHU Helora’s immunology trials aim to provide patients with more effective and safer treatment options.

Studies target bone and joint conditions, evaluating new therapeutics to improve mobility and reduce pain.

• Efficacy of secukinumab in preventing flares of axial spondyloarthritis
• Investigating upadacitinib for structural progression in rheumatoid arthritis
• Bone reconstruction using autologous 3D osteogenic implant NVD-003 for recalcitrant lower‑limb nonunion
• Evaluation of novel biologics in ankylosing spondylitis and juvenile idiopathic arthritis

The musculoskeletal research program supports patients seeking relief from chronic joint disease.

Oncology at CHU Helora spans solid tumors, hematologic malignancies, and targeted therapy development, with a focus on improving survival and disease‑free intervals.

• Adjuvant pembrolizumab plus chemotherapy for high‑risk endometrial cancer
• Combination of camizestrant with endocrine therapy in early breast cancer
• Investigating zilovertamab vedotin versus R‑CHOP in large B‑cell lymphoma
• Neoadjuvant durvalumab plus chemotherapy before surgery for operable non‑small cell lung cancer
• Trials of tarlatamab with durvalumab in extensive‑stage small‑cell lung cancer
• Evaluation of savolitinib plus osimertinib versus chemotherapy in EGFR‑mutated NSCLC

These efforts reflect the site’s dedication to advancing cancer treatment across multiple tumor types.

Research addresses acute cerebrovascular events and progressive neurological disorders, seeking therapies that limit damage and preserve function.

• Safety and tolerability of Ir‑CPI in spontaneous intracerebral haemorrhage
• Evaluation of milvexian after acute ischemic stroke or high‑risk transient ischemic attack
• BTK inhibitor SAR442168 for primary progressive multiple sclerosis
• Long‑term outcomes of adjuvant therapies in acute coronary syndrome with neurological sequelae

The neurological program strives to reduce disability and improve recovery after brain injury.

The metabolic unit explores obesity, weight management, and disorders of uric acid metabolism, aiming to achieve sustainable health improvements.

• Assessment of maridebart cafraglutide for chronic weight management in adults without diabetes
• Comparison of tigulixostat with allopurinol for serum uric acid reduction in gout
• Evaluation of baxdrostat on ambulatory and seated systolic blood pressure in hypertension
• Lifestyle and pharmacologic interventions for metabolic syndrome in high‑risk cardiovascular patients

CHU Helora’s metabolic studies aim to provide effective tools for weight control and related conditions.

Across many disease categories, trials focus on clinical endpoints such as disease‑free survival, recurrence, and symptom relief, providing comprehensive evaluation of treatment impact.

• Disease‑free survival analysis for adjuvant therapies in breast and endometrial cancers
• Endoscopic improvement and symptomatic remission in ulcerative colitis with novel agents
• Structural progression prevention in rheumatoid arthritis using advanced imaging
• Recurrence‑free survival in mismatch‑repair deficient high‑risk endometrial cancer

These outcome‑focused studies support evidence‑based decisions for patient care at CHU Helora.

The site integrates public‑health perspectives, evaluating how environmental factors and population health initiatives influence disease risk and treatment effectiveness.

• Population‑level impact of low‑dose aspirin on colon cancer recurrence and survival
• Assessment of cardiovascular risk reduction in high‑risk individuals without prior events
• Community outreach for early detection of breast and colorectal cancers
• Surveillance of hypertension prevalence and management outcomes in the regional population

CHU Helora’s public‑health research contributes to healthier communities throughout Belgium.